Aims To evaluate the cost-effectiveness of obinutuzumab in combination with bendamustine followed by obinituzumab maintenance (Obin-Benda) compared to bendamustine alone (Benda) in patients with refractory follicular lymphoma (FL) in a Norwegian setting. Methods A three-state area-under-the-curve (AUC) model was developed. The states included were progression-free-survival (PFS), progressed disease (PD), and death. Each state had costs and utilities assigned to it. The pivotal phase III randomized controlled trial GADOLIN was used for clinical input in the model along with Norwegian cost estimates. The trial demonstrated that Obin-Benda improved overall survival (OS), with a hazard ratio (HR) of 0.67 (95% CI 0.47-0.96), and reduced the likelihood of progression or death (HR 0.52, 95% CI 0.39-0.69) compared to Benda. The model used EQ-5D data collected in the GADOLIN trial, with UK tariffs assigned to the EQ-5D scores.
Introduction
Lymphomas are a heterogeneous group of cancers that develop in lymphocytes and produce tumors in lymphoid nodes and in extranodal tissues. Lymphomas can be grouped into Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL) [1] .
Follicular lymphoma (FL) is among the most common subtypes of NHL [2] [3] [4] . In 2015 it was estimated that approximately 9200 patients lived with NHL in Norway, and that about 1000 new patients are diagnosed each year (excluding CLL and small lymphocytic lymphoma) [5] . According to Barzenje et al. [6] , FL comprises 20-25% of NHL. The prevalent cases of FL in Norway would then be between 1800 and 2300 [6] . On a European level, the age-standardized incidence was estimated to be 2.81 per 100,000 people from 2004-2012, with a prevalence of 2.4 in 10,000 people [3] .
Although choice of treatment is highly dependent on patient characteristics, standard of care within advanced stages of FL is rituximab-containing regiments. As firstline treatments in Norway, the typically used regimens are rituximab monotherapy or in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), bendamustine, CVP, chlorambucil, or COP [7] . In the first line, maintenance treatment is used when it is particularly important to prolong remission [8] . The median life expectancy of indolent lymphomas ranges from 5 to 10 years after diagnosis, but some patients live beyond 20 years [9] . Approximately 20% of the patients who have received immunochemotherapy as first-line treatment are expected to progress within two years from diagnosis [10] . Patients who progress during or in the first 6 months after a rituximab-containing regimen have a median progression-free survival of less than a year [11] [12] [13] . Current treatment options for patients who are refractory to rituximab in Norway include bendamustine (monotherapy or combination), or chemotherapy [7] . The median PFS for bendamustine monotherapy has been estimated to be 9.3 months [11] . Obinutuzumab, which is a recombinant monoclonal humanized and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype antibody, is approved in the EU for treating FL in patients who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen [14, p. 2] . The approval was based on the phase III open label trial GADOLIN, NCT01059630 [15] , which demonstrated a significant improvement in progression-free survival (PFS) compared with bendamustine.
The purpose of this study was to investigate the costeffectiveness of obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance ("Obin-Benda") versus bendamustine alone ("Benda") in rituximab refractory FL in Norway. Benda was used as a comparator as it is one of the standard treatments in the rituximab refractory FL setting in Norway, and head-tohead evidence of Obin-Benda versus Benda exists. The cost-effectiveness of obinutuzumab in patients who have relapsed or are refractory to rituximab has previously been investigated in the USA [17] . The study demonstrated that Obin-Benda was cost-effective in the USA in the relapsed and refractory population. However, it is difficult to directly translate cost data from the USA to Norway or any other similar European country due to differences in healthcare systems. When the patient population in the USA is also different, a comparison of results between these two analyses would likely not be meaningful.
Methods

Cost-Effectiveness Model
The cost-effectiveness analysis was based on a three-state area-under-the-curve (AUC) model that used cohort simulation (Fig. 1 ). AUC models are commonly used in the evaluation of oncology drugs for reimbursement purposes. In addition, AUC models are aligned with the endpoints of the pivotal clinical trial, making it easier to construct and communicate [18] . The model consisted of the health states progression-free survival (PFS) (where patients can be either on or off treatment), progressive disease (PD), and death. This approach enabled us to estimate time in PFS state and time in PD state. The time in the PFS-state was calculated as the area under the PFS curve and overall time spent alive was the area under the overall survival (OS) curve. The time in the progression state is calculated as the difference between the OS and PFS. Due to the structural form of the model, patient transitions between the health states are not explicitly modelled. The partitioned survival approach allows for modelling of OS and PFS based on study-observed events, which is expected to accurately reflect disease progression and the long-term expected survival profile of patients treated with obinutuzumab.
All patients start in the progression-free health state, in which they could receive the study drugs or not (on/ off treatment) at each cycle of 1 month. They could subsequently move either to another health state or stay in the same state at the end of each model cycle for a selected time period. The possible flow of patients is indicated by arrows in Fig. 1 . When patients move to the PD-state they incur costs of subsequent treatments. At each cycle, patients incur costs and experience a utility dependent on the health state. Although in principle the modelling time horizon should be long enough to capture any differences in costs and/or effects [16] , we restricted the time horizon to 20 years due to uncertainty of modelling over a longer period. All costs and effects were discounted at an annual rate of 4%, which is in accordance with the Norwegian Medicines Agency's (NoMA) guidelines [19] .
Clinical Input
The model uses clinical data from the GADOLIN trial for the main efficacy inputs. While the main readout of the GADOLIN trial was based on September 2014 data-cut [15] , the model used the readout from April 2016 data-cut [20] , including more mature OS data, which allowed for the above-described AUC model. The trial demonstrated that Obin-Benda improved overall survival (OS), with a hazard ratio (HR) of 0.67 (0.47, 0.96), and reduced the likelihood of progression or death (HR 0.52, 95% CI 0.39-0.69). While the OS data were still immature, a lower proportion of patients had died in the Obin-Benda arm versus the Benda arm (23.8 vs. 37.4%). Parametric survival functions were fitted to the time spent in PFS and OS as observed in the GADOLIN trial. An assumption was made to restrict the OS treatment effect of Obin-Benda by setting the hazard rate for death equal to Benda after the maximum OS follow-up of 5.5 years available in the GADOLIN study. At least until that time point, the survival curves continued to separate (see figure in ESM Appendix). The time point of restricting the efficacy was subsequently explored in sensitivity analyses.
Before fitting parametric survival models, the proportional hazards (PH) assumption was tested by means of the log cumulative hazard plots and Schoenfeld residuals. For both PFS and OS it was concluded that the PH-assumption did not hold. Hence, separate parametric survival models were fitted to each treatment arm [21] . The base-case choice of parametric models was based on the Akaike information criterion (AIC) together with visual inspection and clinical plausibility of the curves (see Tables 5  and 6 in the ESM Appendix). Clinical plausibility was based on previous studies: The patients relevant for this analysis may have relapsed on several treatments, and 46% of patients included in GADOLIN had received two or more treatments prior to inclusion, while 21% had three or more treatments. As previously mentioned, the median life expectancy of indolent lymphomas ranges from 5 to 10 years after diagnosis. Patients who have been through several lines of treatment are expected to have a poorer prognosis than the above-mentioned median life expectancy. For example, a newer study has shown that PFS is shortened by each relapse [22] , and 10-year OS was found to be 46.6% and 16.3% for second and third line, respectively.
For PFS, the Log-Normal and Log-logistic had the best overall fit. However, due to the high proportion of patients in PFS at the end of the model time horizon for Obin-Benda (6% vs. 0% for Benda), it was decided to use a more conservative model, in this case Weibull (0% in PFS after 20 years for both arms). Weibull was also chosen for OS as the Log-Logistic, Log-Normal, and Gamma resulted in a seemingly unrealistic high number of patients alive at the end of the model time horizon, and high incremental gains for Obin-Benda (difference in proportion alive of 5.7%, 6.2%, and 5.9%, respectively; see Table 7 in the ESM Appendix). In contrast, the Weibull model resulted in a difference of 0.9% after 20 years. The Gompertz did not converge for OS, and was hence not evaluated. All parametric functions were explored in sensitivity analyses. The model used EQ-5D-3L data collected in the GADO-LIN trial, with UK tariffs assigned to the EQ-5D scores. In the absence of Norwegian specific tariffs, UK tariffs were selected because it is the preferred tariff by NoMA [19] . The mean value was calculated as arithmetic means over the arithmetic individual means over life state. The data were pooled across treatment arms, because the EQ-5D scores were not statistically significant between the treatment arms. In the model the health state utilities vary between PFS and PD, and within PFS there is a different utility associated with patients who are on or off treatment. No disutility due to adverse events was taken into account.
Costs
The perspective of the analysis was that of the Norwegian healthcare payer and hence only costs directly related to treating the disease were included: administration costs, drug costs, and supportive care costs. Future unrelated healthcare costs were not included, which is in accordance with NoMA's guidelines [19] . Supportive care costs consisted of laboratory costs, radiology costs, and hospitalization costs. Drug costs were pharmacy selling prices excluding value added tax. These selling prices are the maximum prices that the drugs can be sold for in Norway. The administration costs consisted of time costs for specialist nurses, pharmacy costs, and clinical consultation costs.
The treatment duration in the model was based on the observed treatment length in the GADOLIN trial, and was calculated as the time span between the first treatment administration and the last administration of any of the study drugs. The dosing was based on the actual average dose observed, meaning the number of vials was calculated based on the mean amount of drug administered per population and treatment and administration. For each administration in the Obin-Benda arm one vial of obinutuzumab was used. If the first dose is administered on 2 days, it was assumed that the same vial was used. For bendamustine different vial sizes were available, i.e., 25 mg and 100 mg vials. In order to calculate the price of bendamustine, the combination of the number of small and the number of large vials that gave the lowest price was calculated. In the trial, obinutuzumab was administered by IV infusion at a dose of 1,000 mg for six 28-day cycles, on Days 1, 8, and 15 of Cycle 1, and on Day 1 only of Cycles 2-6; and every 2 months thereafter until progression or for up to 2 years (whichever was earlier). The dose of obinutuzumab could be split over two consecutive days in patients whose infusion was prolonged because of an adverse event. The dose of bendamustine in the ObinBenda arm was 90 mg/m 2 per day (Days 1 and 2, Cycles 1-6). Bendamustine in the control arm was administered as monotherapy at a dose of 120 mg/m 2 /day IV on Days 1 and 2 of Cycles 1-6 of each 28-day cycle, for up to six cycles.
Maintenance therapy is usually reserved for rituximabcontaining regimens, and as the included patients were refractory to rituximab, the comparator in the model and clinical trial did not include maintenance. The base case assumed the vials could not be shared between patients.
As a proxy for the cost of subsequent treatments (i.e., after progression) we used the cost of idelalisib, and the cost was assumed to be equal between the two treatment arms. Idelalisib was considered as a post-progression therapy as it is a treatment of choice when patients are refractory to two previous regimes [7] . Costs of idelalisib incur monthly after progression. All costs were adjusted to 2017 NOK by using the consumer price index for Norway and converted to Euros (1 EUR = 9 NOK). The conversion rate used is approximately the average for the last 3 years, and was rounded down. The Appendix lists more details on the costs. The frequency of adverse events was taken from the GADOLIN trial. Grade 3-5 adverse events were included if they were classified as being treatment related, where higher grades indicate more severe adverse events. Costs for adverse events were based on diagnosis-related groups (DRGs) from a Norwegian source [23] , and can be found in the Online Supplementary Material.
A summary of model inputs can be found in Table 1 .
Sensitivity Analyses
One-way sensitivity analyses were conducted by systematically varying input parameters using ± 30% for costs and confidence intervals was used for utilities. One-way sensitivity analyses were conducted on utility, adverse event costs, administration costs, supportive care costs, and costs of subsequent treatments. We also conducted scenario analyses that consisted of changing the duration of efficacy, changing the type of parametric extrapolation and changing the time horizon. In addition, probabilistic sensitivity analyses, 2,000 iterations, were conducted, including the construction of a cost-effectiveness acceptability curve (CEAC), which shows the probability of a given treatment being cost-effective at a range of cost-effectiveness thresholds. Figure 2 shows the model predictions for overall survival and PFS. As can be seen from the figure, some patients are still alive at the end of the time horizon and there is still a difference between the two treatment arms. One can observe a kink in the OS-curve for the Obin-Benda after 5.5 years, where the risk of death is assumed to be the same as for Benda and the curves converge over time. For the numbers at risk, we refer to the publication by Cheson et al. [20] . The cost-effectiveness results are displayed in Table 2 . The expected discounted life-years for a patient on ObinBenda was estimated to be 6.08, while for Benda it was 4.81, resulting in a gain in life-years of 1.27 with the Obin-Benda compared to Benda. The expected discounted QALYs were estimated to be 4.67 for Obin-Benda and 3.65 for Benda, resulting in a gain of 1.02 for Obin-Benda. In terms of 
Results
Main Results
Sensitivity Analyses
The one-way sensitivity analyses indicate that few of the tested parameters had a large impact on the ICER with the exception of the utility values, which could change the ICER up to €58,715 or down to €39,855 per QALY gained (see Table in the Appendix). When it comes to the scenario analyses, the impact of changing the duration of efficacy was large (ICER = €71,914 with 3 years of efficacy, and €38,622 with 8 years), but otherwise the model was not highly sensitive to changes in these parameters. The probabilistic results indicated an ICER of €46,887 per QALY gained (95% CI €34,772-€59,443). Figure 3 displays the cost-effectiveness acceptability curve (CEAC). The CEAC illustrates the probability that each treatment arm is the cost-effective alternative at a range of willingness-to-pay thresholds. Obin-Benda has the highest probability of being cost-effective at a threshold of approximately €48,900 and above. 
Discussion
The results indicate an ICER of €46,438 per QALY gained. Severity of the disease, as measured by absolute QALY shortfall [24] , has an impact on which treatments are considered cost-effective in Norway for drugs purchased by the public sector. According to NoMA's calculations, the absolute shortfall for the patient population in question is approximately 12 QALYs, making it a severe disease [7] . Absolute shortfall is calculated using the QALYs of patients in the comparator arm in the cost-effectiveness model, and subtracting from the expected prognosis of the general population at the same age, based on data from Statistics Norway [25] and Swedish age-specific HRQoL data with UK tariffs [26, 27] . For a patient aged 62 years, as in the model, the expected prognosis is 17.4 QALYs. There is no public costeffectiveness threshold in Norway, but it can be assumed to be up to €89,000 (NOK 800,000) based on previous recommendations by NoMA and the regional hospital enterprises, depending on the severity of the disease and uncertainty. For this reason, obinutuzumab in combination with bendamustine for the treatment of rituximab-refractory follicular lymphoma in Norway may be cost-effective compared to a standard of care. These results are supported by the conducted sensitivity analyses. A key uncertainty in the analysis is the OS benefit of Obin-Benda. The OS-data were immature. At the trial cutoff 24% and 37% of patients had died in the Obin-Benda and Benda arms, respectively. In addition, the trial was openlabel, which may have had an impact on how the investigators and patients reported outcomes, e.g. progression and health-related quality of life (HRQoL). If patients are more positively inclined to the new intervention, they may have a tendency to report a higher HRQoL with the new intervention compared to the comparator. This could potentially result in a lower ICER. However, in our analysis we grouped together HRQoL for both treatment arms, which should lower the impact of this bias. It is also uncertain how the patients fare after treatment. Treatment with ObinBenda is stopped after 30 months, and the duration of efficacy after this point is uncertain. In the present analysis we assumed that the risk of death would be equal between the two arms after 5.5 years, and the scenario analyses indicated that this parameter had a high impact on the ICER. At 5.5 years many patients are censored, but we considered this the best evidence available and that it pointed towards efficacy at least until this time point. However, we considered limiting the treatment effect to 5.5 years conservative, and that the effect could also last longer. In clinical practice the efficacy in both arms could also be assumed to increase if patients get additional treatments after discontinuation, which is not captured in the model. The model results show a difference in median life-years in PFS versus mean life-years in PFS, which indicates that the model results in some patients living for a long time, particularly for the Obin-Benda arm.
Bendamustine is one of several treatments that are used for rituximab refractory FL. The study did not include comparisons versus rituximab due to the fact that patients were rituximab-refractory. The feasibility of comparing to other chemotherapies was explored before conducting the analysis, and it was found not feasible due to difficulties establishing a network for an indirect treatment comparison. The benefit of comparing to bendamustine is that it allows the use of direct clinical trial data, which we consider more robust than using an indirect comparison.
Before this study there had been no data on the cost-effectiveness of obinutuzumab in combination with bendamustine for the treatment of rituximab refractory FL in Norway. 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 1,00,000 Probability of being cost-effective
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Obin-Benda Benda
The study was conducted in association with the national reimbursement process, and was intended to enable the authorities to make a decision regarding implementation of the treatment in Norway. The model and assumptions have been evaluated by NoMA, and a report on the evaluation can be found online [7] . The present study took into account feedback from NoMA on using individual parametrization of overall survival, and sensitivity analyses have also been added. NoMA changed some of the assumptions in the model with the result being that the ICER increased to approximately €71,000. The main differences were that the time horizon was changed to 10 years (from 20 years), and that the treatment effect duration was changed from 5.5 years to 3.9 years. According to NoMA, the ICER was in the upper bounds of what is normally considered cost-effective. The treatment was implemented in hospitals in June 2017 based on NoMA's conclusion. A 10-year time horizon for FL, which is an indolent disease, is likely to be too short because many patients would still be alive at the end of the model time horizon, and there would still be a difference between the two patient groups that will not be captured. Setting a 3.9-year limit on treatment efficacy is plausible considering the number of censored patients towards the end of the clinical trial follow-up. It seems 3.9 years was used since this is the time of the last event in the Obin-Benda arm; however, this does not allow for any extrapolation of treatment effect, which is common practice in CEAs. The assumption of a duration of efficacy of more than 3.9 years is supported by data on patients who have been followed up for longer in GADOLIN, and is also supported by the efficacy seen on PFS.
Conclusions
The results of the cost-effectiveness analysis indicate that obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance may be cost-effective compared to bendamustine alone in Norway.
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